Micoy Therapeutics creates engineered protein decoys and rapid point‑of‑care blood tests to detect and neutralize harmful autoantibodies against Type I interferons and the folate receptor alpha.
Funding
Funding not disclosed
Founders
Product
Problem
Autoantibodies that target Type I interferons and the folate receptor alpha can silently impair antiviral immunity, fertility, pregnancy maintenance, and neurodevelopment, yet they are not routinely screened in clinical practice.
Solution
Micoy Therapeutics builds a combined platform of engineered decoy biologics and rapid blood‑based diagnostics to neutralize these pathogenic autoantibodies. For Type I interferon autoantibodies, the company develops therapeutic decoys that bind and sequester the antibodies, restoring normal interferon signaling. For folate receptor alpha autoantibodies, Micoy offers NeuroLume™, a finger‑prick test that detects the antibodies within minutes, enabling early identification of at‑risk individuals. By linking precise detection with targeted neutralization, the platform aims to re‑establish immune balance, protect pregnancies, and reduce long‑term neurodevelopmental risk.
Target Audience
Primary customers are clinicians and healthcare systems managing patients at risk of severe viral infections, infertility, recurrent pregnancy loss, or neurodevelopmental disorders, as well as specialty laboratories offering rapid autoantibody testing.
Features
- Engineered protein decoys designed to specifically bind and inactivate Type I interferon autoantibodies without compromising endogenous cytokine function
- NeuroLume™ rapid point‑of‑care assay that detects folate receptor alpha autoantibodies from a finger‑prick sample in minutes
- Integrated diagnostic‑therapeutic workflow that pairs antibody detection with immediate therapeutic intervention
- Proprietary protein‑engineering pipeline that optimizes affinity and safety of decoy biologics
- Scalable blood‑test format compatible with standard clinical laboratory equipment and bedside use